Aethlon Medical (AEMD) Expected to Announce Earnings on Wednesday

Aethlon Medical (NASDAQ:AEMD) is expected to release its Q3 2026 results before the market opens on Wednesday, February 11th. Analysts expect the company to announce earnings of ($2.01) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earning overview page for the latest details on the call scheduled for Wednesday, February 11, 2026 at 4:30 PM ET.

Aethlon Medical (NASDAQ:AEMD) last released its quarterly earnings results on Wednesday, November 12th. The medical equipment provider reported ($3.74) EPS for the quarter, missing analysts’ consensus estimates of ($1.70) by ($2.04). On average, analysts expect Aethlon Medical to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Aethlon Medical Trading Down 2.9%

Shares of NASDAQ:AEMD opened at $2.33 on Wednesday. The company has a 50 day moving average of $3.04 and a 200-day moving average of $6.80. The firm has a market cap of $2.26 million, a P/E ratio of -0.10 and a beta of 1.60. Aethlon Medical has a twelve month low of $2.22 and a twelve month high of $64.00.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Aethlon Medical in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Reduce” and an average target price of $560.00.

Institutional Trading of Aethlon Medical

A hedge fund recently bought a new stake in Aethlon Medical stock. Citadel Advisors LLC purchased a new stake in shares of Aethlon Medical, Inc. (NASDAQ:AEMD) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned 36.57% of Aethlon Medical at the end of the most recent reporting period. 1.99% of the stock is owned by institutional investors.

Aethlon Medical Company Profile

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.